TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01437449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m² by intravenous (IV) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 30 mg/m² by intravenous (IV) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m² by intravenous (IV) administration, thereafter 250 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the free carboplatin plasma concentration versus time curve (AUC)=2 by intravenous (IV) administration
Study: NCT03491605

Intervention type: OTHER
Intervention: peripheral EBV-DNA load
Description: No intervention
Study: NCT02922803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 combination tablet of Vitamin D3/calcium per day
Description: Combination tablet of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 combination tablets of Vitamin D3/calcium per day
Description: Combination tablets of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
Study: NCT00001651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [6,6-2H2]-glucose
Description: \[6,6-2H2\]-glucose will be administered as a continuous IV infusion for one to five days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [6,6-2H2]-glucose
Description: \[6,6-2H2\]-glucose will be administered as a continuous IV infusion for one to five days.
Study: NCT03848533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Description: The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled Medication 2 to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Description: The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled Medication 2 to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled Medication 1 to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled Medication 1 to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)
Study: NCT00634608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Information Prescription
Description: The patient education materials will consist of approximately 21 topics representing some of the most common conditions seen at the Fairview Internal Medicine Clinic. Twenty-one e-mails, one per topic, will be created by Fairview physicians to be distributed to selected clinic patients. There will be a standard e-mail for each condition with a specific link to MedlinePlus. To create the targeted health information topic email, the physician will review the information available at MedlinePlus. The physician will then select several links of appropriate information and, using the template, will write a short annotation on each link.
Study: NCT00875680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoPPC
Description: To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
Study: NCT01714128

Intervention type: DRUG
Group type: OTHER
Intervention: Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))
Description: FES-PET/CT imaging
Study: NCT02243033

Intervention type: DEVICE
Intervention: MR-guided laser focal therapy
Description: Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.
Study: NCT01640691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine (H5N1)
Description: Inactivated whole-virion vaccine~1. Administration route: Intramuscular Injection~2. Dosing schedule: 2 injections - at Day 1 and Day 22 separately~3. Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)
Study: NCT00360529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin
Description: flibanserin placebo versus 50 mg qhs versus 100 mg qhs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin
Description: flibanserin placebo versus 50 mg qhs versus 100 mg qhs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: flibanserin
Description: flibanserin placebo versus 50 mg qhs versus 100 mg qhs
Study: NCT04465006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy Simulator
Description: Patients in the hippotherapy simulator group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 45 minutes of Neurodevelopmental treatment exercises and 15 minutes of hippotherapy simulation exercise program were applied to the participants in this group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercise
Description: Patients in the conventionnal exercise group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 60 minutes of Neurodevelopmental treatment exercises were applied to the participants in this group.
Study: NCT04730297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol 500 mg plus codeine 30 mg preoperative administration
Description: each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen 400 mg preoperative administration
Description: each patient 30 minutes before surgery received ibuprofen 400 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet preoperative administration
Description: each patient 30 minutes before surgery received placebo
Study: NCT03652753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 4 mL of a 20% solution of NAC will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 4 mL of a 20% solution of saline will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
Study: NCT02157038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT03103555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
Study: NCT02649868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial embolization (TAE)
Description: Transarterial embolization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC Bead LUMI
Description: LC Bead LUMI has been designed as a radiopaque version of the LC Bead
Study: NCT04074980

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venous and Fingerstick blood draws
Description: Fingerstick sampling to collect blood from subjects Venepuncture to collect blood samples from subjects

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venous blood draw
Description: Venepuncture to collect blood samples from subjects
Study: NCT01055366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elazop (Azarga)
Description: Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
Study: NCT02534857

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: a shorter exposure of oocyte to spermatozoa
Description: Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a shorter exposure of oocyte to spermatozoa
Description: Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
Study: NCT03297840

Intervention type: BEHAVIORAL
Intervention: Dialectical Behavioural Therapy (DBT)
Description: Inpatient Dialectical Behavioural Therapy (DBT) according to Linehan.
Study: NCT01445899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04523655 (Stratum I)
Description: PF-04523655 (a small interfering RNA) - a single IVT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 6 monthly IVT injections of ranibizumab (Stratum II)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 6 monthly IVT injections of ranibizumab (Stratum II)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04523655 (Stratum II)
Description: 6 monthly IVT injections of PF-04523655 (a small interfering RNA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04523655 (Stratum II)
Description: 6 monthly IVT injections of PF-04523655 (a small interfering RNA)
Study: NCT03708198

Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Bupivacaine
Description: intercostal block
Study: NCT01438866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fissure sealant
Description: Preventing dental caries in primary molars by applying fissure sealants and fluoride varnish, and comparing caries preventive effect of sealants with fluoride varnish.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fissure sealants and fluoride varnish
Description: Comparing preventive effect of fissure sealants and fluoride varnish on occlusal surfaces of primary molars
Study: NCT02289300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCB-BO1202
Description: The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The assignment will be as follows:~Placebo: 4 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCB-BO1202+Placebo
Description: The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)
Study: NCT04417959

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phaco-DSAEK
Description: The intervention will be performed as a DSAEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DSAEK.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phaco-DMEK
Description: The intervention will be performed as a DMEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DMEK.
Study: NCT01218438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10% Solution
Description: Intravenous infusion with IGIV, 10%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Subcutaneous (Human), 20% Solution
Description: Subcutaneous infusion with IGSC, 20%
Study: NCT05999994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study: NCT04170959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg given 14 days before start until the end of radiation therapy. Once daily during the first 7 days, afterwards twice daily until the end of treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: No metformin
Description: Standard of care without metformin.
Study: NCT02879747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth
Study: NCT02998333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical stabilization
Description: Surgical stabilization of the ankle joint, performed as an open or arthroscopic procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical stabilization
Description: Surgical stabilization of the ankle joint, performed as an open or arthroscopic procedure.
Study: NCT03853083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypoxi Equipment
Description: Using the Hypoxi exercise equipment to try and improve lipedema fat tissue

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Recumbent Bicycle
Description: Recumbent bike is a piece of exercise equipment used as the comparison group
Study: NCT01119976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced calorie diet and exercise plan
Description: Participants will receive written diet and exercise instructions to follow for the duration of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Different reduced calorie diet and exercise plan
Description: Participants will receive written diet and exercise instructions to follow for the duration of the study.
Study: NCT02683187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Sitagliptin
Description: Subjects will receive sitagliptin prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator - No Sitagliptin
Description: Subjects will receive Placebo (instead of sitagliptin) prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
Study: NCT03220763

Intervention type: OTHER
Intervention: This is an observational study--there is no intervention.
Description: This is an observational study, there is no intervention.
Study: NCT01427075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LATERAL PHARYNGOPLASTY
Description: tonsilectomy and lateral pharyngoplasty
Study: NCT01697293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triciribine Phosphate
Description: Given IV
Study: NCT01133652

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Veinviewer
Description: Veinviewer machine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: Conventional IV placement by nurses
Study: NCT02040402

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugated vaccine
Description: Pneumococcal vaccine 3+1 and 2+1 schedule comparison

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugated vaccine
Description: 3+1 doses vs 2+1 doses
Study: NCT03118960

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freedom Bed
Description: This is an automatic rotational system in a bed designed to disburse capillary pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group II Low Air Loss/Alternating Pressure Mattress
Description: Subjects placed on the Group II Low Air Loss/Alternating Pressure Mattresses will require manual repositioning every 2 hours
Study: NCT02587351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: Extended release Metoprolol succinate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT00386906

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel Lymph Node Mapping and Biopsy
Description: Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
Study: NCT03815721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulette r2x+
Description: device for repetitive transcutaneous spinal cord stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulette r2x+
Description: device for repetitive transcutaneous spinal cord stimulation
Study: NCT02300714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oblique view approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oblique view approach
Study: NCT00613951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c., twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 1500-2000 mg/daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1500-2000 mg/daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1500-2000 mg/daily
Study: NCT03353818

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Golf
Description: A free golf course and free membership for one year in a golf club will be given to participants.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: Patients acting as controls will not be restricted in any ways.
Study: NCT03080129

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresubin energy
Description: dietary protein energy supplement
Study: NCT03998527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Spinal Cord Stimulation (TcESCS)
Description: TcESCS is a non-invasive DC battery powered device. Investigators and/or research team members will continually assess the appropriate stimulation parameters including configurations, current, voltage and frequency delivered by up to five active electrodes applied on skin of the back from cervical to lumbar levels. Stimulation parameters used during experimental assessments and interventions will be closely monitored by the research team. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, respiratory rate, and electromyography will be closely monitored while we are determining the correct stimulation parameters in the lab. During the stimulation training sessions, we will monitor blood pressure regularly throughout the session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Spinal Cord Stimulation (TcESCS)
Description: TcESCS is a non-invasive DC battery powered device. Investigators and/or research team members will continually assess the appropriate stimulation parameters including configurations, current, voltage and frequency delivered by up to five active electrodes applied on skin of the back from cervical to lumbar levels. Stimulation parameters used during experimental assessments and interventions will be closely monitored by the research team. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, respiratory rate, and electromyography will be closely monitored while we are determining the correct stimulation parameters in the lab. During the stimulation training sessions, we will monitor blood pressure regularly throughout the session.
Study: NCT03007823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-activity natural killer
Description: Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
Study: NCT03953027

Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02459067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ImmuniCell®
Description: Autologous γδ T Lymphocytes
Study: NCT05115162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercises consist of flexibility, strengthening exercises for the trunk and extremities, and walking indoors.The walking program was applied for at least 30 minutes. Eight different exercises were given for the trunk and extremities and these exercises were applied 3 times a week, 2 sets, each set with 10 repetitions.